Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial
Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in…
Novo’s oral semaglutide outperforms Jardiance in late-stage study
Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met…